WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 14, Issue 21, 728-741. Research Article ISSN 2277–7105

THE PITUITARY POWERHOUSE: PHARMACOLOGY AND THERAPEUTIC APPLICATIONS OF ITS HORMONES

Nikhil M. Khatwani[1]*, Yash P. Kamble[1], Atish B. Kawade[1], Prajwal N. Bambole[1], Chetna P. Hiwase[1], Vrushabh N. Hete[1], Dr. Kamlesh J. Wadher[1]

[1]*K. D. K. College of Pharmacy and Research Institute, Nagpur.

Article Received on 27 Sept. 2025,
Article Revised on 17 October 2025,
Article Published on 01 Nov. 2025,

https://www.doi.org/10.5281/zenodo.17471724

***Corresponding Author**
Nikhil M. Khatwani
K. D. K. College of Pharmacy and Research Institute, Nagpur.

How to cite this Article: Nikhil M. Khatwani, Yash P. Kamble, Atish B. Kawade, Prajwal N. Bambole, Chetna P. Hiwase, Vrushabh N. Hete, Dr. Kamlesh J. Wadher. (2025). The Pituitary Powerhouse: Pharmacology And Therapeutic Applications Of Its Hormones. World Journal of Pharmaceutical Research, 14(21), 728–741.

ABSTRACT

The pituitary gland – often called the "master gland" – secretes hormones that regulate growth, metabolism, stress responses, reproduction, and water balance. These hormones include growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), vasopressin (ADH), and oxytocin. The pituitary gland plays an important role in the regulation of growth, differentiation and function of cells, including immunocytes. We highlight major therapies that mimic or modulate pituitary hormones – for example, recombinant GH (somatropin) for GH deficiency, desmopressin for diabetes insipidus, dopamine agonists (bromocriptine, cabergoline) for hyperprolactinemia, and GnRH analogs (leuprolide) for sex hormone disorders. Emerging advances, long-acting formulations, and challenges in hormone drug design are discussed, providing a detailed overview for pharmacy students and healthcare professionals.

KEYWORDS: Pituitary gland, Growth hormone, Adrenocorticotropic hormone, Thyroid-stimulating hormone, Luteinizing hormone, Follicle-stimulating hormone.

INTRODUCTION

The endocrine system relies on creating and releasing hormones to coordinate bodily functions. The pituitary gland, located at the brain's base, integrates hypothalamic signals and secretes hormones that act on peripheral glands and tissues.[1] Because it controls other

endocrine glands, the pituitary is termed the "master gland".[2] Structurally, it has an anterior lobe (adenohypophysis) and posterior lobe (neurohypophysis).[3] The anterior pituitary cells (somatotropes, lactotropes, corticotropes, thyrotropes, gonadotropes) secrete GH, PRL, ACTH, TSH, LH and FSH.[4] The posterior pituitary releases neuropeptides vasopressin (ADH) and oxytocin, synthesized in the hypothalamus.[5] Through a network of feedback loops, these hormones maintain homeostasis.[6] For example, GH promotes growth and metabolism (via IGF-1), ACTH stimulates cortisol production, TSH drives thyroid hormones, LH/FSH regulate gonads, ADH controls water balance, and oxytocin mediates parturition and lactation.[7] Dysfunction in pituitary secretion leads to diverse disorders (e.g., growth failure or acromegaly from GH imbalance, diabetes insipidus from ADH deficiency, amenorrhea from prolactin excess).[8] This article reviews each major pituitary hormone's physiology and clinical impact, then focuses on pharmaceutical agents that replace or mimic these hormones (e.g., somatropin, desmopressin) or block their effects (e.g., pegvisomant, dopamine agonists).[9]

A comprehensive literature search was conducted to gather up-to-date information on pituitary hormones and related pharmacotherapy.[10] PubMed and Google Scholar were queried with terms such as "pituitary hormone," "growth hormone therapy," "gonadotropin analog," "desmopressin," "bromocriptine," and "leuprolide."[11] Priority was given to recent (2015–2025) peer-reviewed reviews, clinical guidelines, and drug monographs.[12] Foundational endocrine textbooks and statpearls summaries provided background.[13] Key references were identified by reviewing the citations of relevant articles.[14] Data on drug mechanisms, indications, and new therapeutic developments were extracted.[15] The resulting review synthesizes biological roles of each hormone, clinical conditions of deficiency or excess, and the pharmacological agents used to treat these conditions, with an emphasis on mechanism of action and clinical use.[16]

RESULTS/FINDINGS

Growth Hormone (GH)

GH is secreted by pituitary somatotropes under hypothalamic regulation.[17] It stimulates linear growth (via IGF-1), protein synthesis, and lipolysis, and antagonizes insulin action to raise blood glucose.[18] GH deficiency in children causes growth retardation and short stature (dwarfism), while adult GH deficiency leads to increased adiposity, reduced muscle mass, and adverse cardiovascular risk.[19] Conversely, GH excess causes gigantism in children and

acromegaly in adults (coarse facial features, organomegaly, insulin resistance).[20] GH is involved in metabolism throughout life and influences bone density and muscle strength.[21]

Clinically, GH deficiency (GHD) may be primary or secondary (e.g., pituitary tumor surgery).[22] Adult GHD symptoms can be subtle (fatigue, dyslipidemia).[23] Acromegaly is most often due to a GH-secreting pituitary adenoma, leading to increased IGF-1, arthritis, cardiomyopathy, and elevated risk of diabetes.[24] Diagnosis of GH disorders relies on dynamic testing (e.g., GH stimulation or suppression tests, IGF-1 levels).[25]

Prolactin (PRL)

PRL is produced by lactotrophs and primarily promotes mammary gland development and lactation.[26] It is unique among pituitary hormones because its main control is inhibitory via hypothalamic dopamine.[27] Physiologically, PRL levels rise in pregnancy and breastfeeding.[28] Excess prolactin (hyperprolactinemia) commonly arises from a prolactin-secreting adenoma (prolactinoma), hypothyroidism (increased TRH), or dopamine antagonist medications.[29] Hyperprolactinemia causes galactorrhea, amenorrhea, infertility in women and hypogonadism (low testosterone), decreased libido, and infertility in men.[30] PRL deficiency is rare and has little clinical consequence.[31]

Adrenocorticotropic Hormone (ACTH)

ACTH is a peptide that stimulates cortisol release from the adrenal cortex.[32] It is derived from POMC and released by corticotropes.[33] ACTH secretion follows diurnal rhythm and stress-induced CRH/AVP signals.[34] ACTH deficiency (secondary adrenal insufficiency) results in cortisol deficiency (fatigue, hypotension, weight loss), but aldosterone is usually normal.[35] ACTH excess (from a pituitary adenoma – Cushing disease) leads to hypercortisolism (Cushing syndrome: truncal obesity, hypertension, diabetes).[36] Pituitary ACTH assays and stimulation tests (e.g., cosyntropin test) are used diagnostically.[37]

Thyroid-Stimulating Hormone (TSH)

TSH from thyrotropes drives thyroid hormone production.[38] It is a glycoprotein with α/β subunits similar to LH/FSH.[39] TSH secretion is regulated by TRH and negative feedback from T3/T4.[40] TSH deficiency (central hypothyroidism) causes low thyroid hormones with inappropriately normal/low TSH.[41] Excess TSH (very rare TSH-secreting adenoma) causes hyperthyroidism.[42] In practice pituitary insufficiency of TSH is treated by levothyroxine (target-organ hormone) rather than TSH itself.[43]

Gonadotropins (FSH, LH)

FSH and LH are secreted by gonadotropes and control the gonads.[44] FSH stimulates ovarian follicle development and spermatogenesis; LH triggers ovulation and testosterone synthesis.[45] These gonadotropins are glycoproteins (sharing the α-subunit).[46] Inhibin and sex steroids provide feedback.[47] Gonadotropin deficiency (secondary hypogonadism) leads to impaired puberty, amenorrhea, infertility, and low sex steroids.[48] Excess LH/FSH can occur with gonadotropin-secreting tumors (rare, causing precocious puberty).[49] Disorders of gonadotropins often present as infertility or sexual dysfunction.[50]

Vasopressin (Antidiuretic Hormone, ADH)

ADH (arginine vasopressin) is a peptide released from the posterior pituitary in response to high plasma osmolality or low blood pressure.[51] It acts on renal V2 receptors to increase water reabsorption, concentrating urine, and on vascular V1 receptors to cause vasoconstriction.[52] ADH deficiency causes central diabetes insipidus (polyuria, polydipsia, dilute urine).[53] ADH excess produces the Syndrome of Inappropriate ADH (SIADH): water retention, hyponatremia and concentrated urine, potentially leading to cerebral edema.[54]

Oxytocin

Oxytocin is a peptide hormone released from the posterior pituitary that induces uterine smooth muscle contraction during labor and promotes milk ejection from mammary glands during breastfeeding.[55] It is synthesized in hypothalamic magnocellular neurons and released in response to cervical stretch or nipple stimulation.[56] Oxytocin deficiency is not clinically recognized in humans, while insufficient oxytocin effect (poor uterine contraction) can contribute to postpartum haemorrhage.[57] Excessive oxytocin is rare except as a drug effect.[58]



Fig. 1: Endocrine Glands.

Pharmaceutical Focus

Major pharmaceutical agents that target pituitary hormones or their axes include both hormone replacements/analogs and receptor modulators. These are summarized below:

- **Growth hormone axis**

Somatropin (recombinant human GH) is used as replacement therapy in GH deficiency (children and adults) and in conditions like Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, and idiopathic short stature.[59] Long-acting GH preparations (e.g., somapacitan, lonapegsomatropin) have been developed to improve adherence by reducing injection frequency.[60] For GH excess (acromegaly), *somatostatin analogs* (e.g., octreotide, lanreotide) and the GH receptor antagonist *pegvisomant* (Somavert) are used.[61] Octreotide binds somatostatin receptors to inhibit GH secretion.[62] Pegvisomant, a modified GH molecule, blocks the GH receptor and normalizes IGF-1.[63]

- **Prolactin axis**

Dopamine agonists are the cornerstone of therapy for hyperprolactinemia.[64] *Bromocriptine* and *cabergoline* (ergot derivatives) stimulate D2 receptors, inhibiting prolactin release and shrinking prolactinomas.[65] Bromocriptine is a shorter-acting D2 agonist, while cabergoline has higher D2 affinity and longer duration.[66] These drugs effectively normalize prolactin levels and restore gonadal function.[67] There are no specific drugs to *increase* prolactin since deficiency is rare; prolactin deficiency is generally not treated pharmacologically.[68]

- **ACTH/corticotropin axis**

The synthetic *cosyntropin* (ACTH_1–24) is used diagnostically to stimulate cortisol release from the adrenals.[69] It has limited therapeutic use except transiently in infantile spasms.[70] A naturally derived *repository corticotropin* (H.P. Acthar Gel) containing full-length ACTH analogs is FDA-approved for infantile spasms and has been used for refractory multiple sclerosis relapses.[71] Acthar's mechanism includes stimulating adrenal steroidogenesis and other melanocortin pathways.[72] In routine hypoadrenalism, oral glucocorticoid replacement (hydrocortisone) is preferred over ACTH analogues.[73]

- **Thyrotropin (TSH)** – Recombinant human TSH (*thyrotropin alfa*, brand Thyrogen) is used as an adjunct in differentiated thyroid cancer management.[74] Given after thyroidectomy, it stimulates any residual thyroid tissue or cancer to uptake radioactive iodine and raises thyroglobulin for diagnostics.[75] Thyrogen is FDA-approved for radioiodine remnant ablation and for thyroglobulin testing in follow-up.[76] There is no approved *TSH* replacement for pituitary insufficiency in other contexts; hypothyroidism is managed with levothyroxine (thyroid hormone) directly.[77]

- **Gonadotropins and GnRH analogs** – For sex hormone regulation and fertility, several pituitary-related drugs exist. *GnRH agonists* (e.g. leuprolide, goserelin, triptorelin) initially stimulate then suppress LH/FSH, leading to downregulation of gonadal sex steroids.[78] Leuprolide is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, precocious puberty and other hormone-dependent disorders.[79] Its continuous use suppresses ovarian/testicular function.[80] *GnRH antagonists* (e.g. cetrorelix, ganirelix) immediately block GnRH receptors, quickly lowering LH/FSH; these are used in IVF protocols and for rapid blockade in prostate cancer (degarelix).[81] Recombinant FSH (*follitropin alpha* e.g. Gonal-F, Follistim) and combined human menopausal gonadotropins (hMG, containing FSH and LH activity, e.g. Menopur) are injected to stimulate ovarian follicle development in infertility treatments.[82] *Human chorionic gonadotropin (hCG)*, although placental in origin, is a surrogate for LH used to trigger ovulation/mature oocytes.[83]

- **Vasopressin (ADH) analogs and antagonists**

The synthetic *desmopressin* (DDAVP) is a potent V2 receptor agonist (minimal V1 activity) and is the treatment of choice for central diabetes insipidus.[84] Desmopressin is administered orally, intranasally, or parenterally to reduce urinary water loss.[85] It is also used in von

Willebrand disease or mild hemophilia A (V2 effect on factor release).[86] For SIADH, V2 receptor *antagonists* (the "vaptans", e.g., tolvaptan, conivaptan) are used to increase free water excretion.[87] They block vasopressin's renal effect and correct hyponatremia.[88] In hypotensive shock or variceal bleeding, vasopressin or analogues (terlipressin) act via V1 receptors as vasopressors, but these are mostly outside endocrine therapy.[89]

- **Oxytocin**

Synthetic oxytocin (Pitocin) is widely used in obstetrics to induce or augment labor by activating uterine contractions.[90] It also treats postpartum hemorrhage by promoting uterine tone.[91] There are no major oxytocin antagonists in clinical use in most countries (the tocolytic *atosiban* is used in Europe to inhibit premature labor by blocking oxytocin receptors, but it is not FDA-approved in the U.S.).[92] Therapeutic advances in pituitary hormone pharmacology have focused on improving delivery and selectivity of peptide hormones. Long-acting formulations now extend the duration of GH therapy (e.g. pegylated or fusion protein GH analogs) and gonadotropin therapy (long-acting FSH). Modern *long-acting GH* preparations (four types in late-stage development) achieve stable IGF-1 levels with once-weekly dosing, improving adherence compared to daily injections.

Similarly, depot preparations of GnRH analogs and extended-release peptides reduce injection frequency. Gene therapy approaches for pituitary deficiencies remain experimental; current research explores small-molecule agonists (e.g., ghrelin receptor agonists for GH release) and oral peptide analogs. Challenges persist due to the peptide nature of these hormones. Injectable administration is often required, and maintaining stability and activity is complex. Immunogenicity (antibody formation) can reduce efficacy. Safety issues include metabolic effects (e.g., GH therapy may worsen glucose tolerance) and serious adverse reactions (e.g., hyponatremia with desmopressin). Drug interactions and off-target effects also arise (e.g., dopamine agonists causing nausea or orthostasis). Cost is substantial for biologic therapies; for instance, GH and Acthar Gel are extremely expensive. Emerging research is addressing these challenges. Oral non-peptide mimetics and long-acting injectables are in trials. For example, orally bioavailable GH secretagogues (ghrelin agonists) and selective oxytocin modulators are under investigation. Precision medicine approaches (tailoring dose to hormone levels or genotype) aim to optimize therapy.

Hormone	Major Function/Target	Therapeutic Indication(s)
GH	Stimulates growth (IGF-1), metabolism	GH deficiency (children/adults); Turner, Prader-Willi, idiopathic short stature; Acromegaly (pegvisomant, octreotide)[93]
Prolactin	Promotes lactation, breast development	Hyperprolactinemia (prolactinomas, pituitary-induced amenorrhea)[94]
ACTH	Stimulates cortisol release	Diagnostic adrenal insufficiency (cosyntropin test); Infantile spasms, MS relapse (Acthar)[95]
TSH	Stimulates thyroid hormone	Thyroid cancer follow-up: radioiodine ablation and Tg testing[96]
LH/FSH	Regulate gonads (ovaries/testes)	Prostate cancer, endometriosis, precocious puberty (GnRH agonists); IVF/ovulation induction (FSH, hMG, hCG); suppressed IVF protocols (GnRH antagonists)[97]
ADH (Vasopressin)	Water reabsorption, vasoconstriction	Central diabetes insipidus (desmopressin); SIADH/hyponatremia (vaptans)[98]
Oxytocin	Uterine contraction, milk ejection	Labor induction/augmentation; Postpartum hemorrhage control[99]

CONCLUSIONS

Pituitary hormones orchestrate a wide range of physiological processes. Modern medicine has developed effective pharmaceutical agents to replace deficient pituitary hormones or counteract their excess. Recombinant analogs (somatropin, desmopressin, thyrotropin) and receptor-targeted drugs (dopamine agonists, pegvisomant, GnRH analogs) have transformed the management of endocrine disorders. Advances in biotechnology have led to long-acting formulations and refined peptide analogs, enhancing convenience and specificity. Nevertheless, challenges remain in drug delivery, cost, and safety. Future directions include novel delivery systems, non-invasive peptide mimetics, and deeper insights into hormone action for therapeutic innovation. A thorough grasp of pituitary endocrinology remains essential for developing and applying these therapies in clinical practice.

REFERENCES

1. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology*. 14th ed. Philadelphia: Elsevier, 2020; 78-82.

2. Martini FH, Nath JL, Bartholomew EF. *Fundamentals of Anatomy and Physiology.* 11th ed. Pearson, 2018; 605-610.
3. Boron WF, Boulpaep EL. *Medical Physiology.* 3rd ed. Philadelphia: Elsevier; 2017; 1002-1007.
4. Goodman HM. *Basic Medical Endocrinology.* 4th ed. San Diego: Academic Press; 2009; 121-130.
5. Ganong WF. *Review of Medical Physiology.* 26th ed. McGraw-Hill Education; 2019; 331-338.
6. Widmaier EP, Raff H, Strang KT. *Vander's Human Physiology: The Mechanisms of Body Function.* 15th ed. McGraw-Hill Education, 2022; 481-485.
7. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment. *J Clin. Endocrinol Metab.*, 2016; 101(5): 1889–1916.
8. Melmed S. Acromegaly pathogenesis and treatment. *J Clin. Invest.* 2009; 119(11): 3189–3202.
9. Colao A, Grasso LF, Giustina A, Melmed S, Chanson P, Pereira AM. Acromegaly. *Nat Rev Dis Primers.*, 2019; 5(1): 20.
10. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology.* 14th ed. Philadelphia: Elsevier; 2021; 931-933.
11. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 136-138.
12. American Association of Clinical Endocrinology (AACE). Clinical practice guidelines for endocrine disorders. *Endocr Pract.*, 2020; 26(Suppl 1): 1-46.
13. StatPearls [Internet]. Pituitary Gland Overview. Treasure Island (FL): StatPearls Publishing, 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279031/
14. Goodman HM. *Basic Medical Endocrinology.* 4th ed. San Diego: Academic Press; 2009; 1-4.
15. Widmaier EP, Raff H, Strang KT. *Vander's Human Physiology: The Mechanisms of Body Function.* 15th ed. McGraw-Hill Education, 2022; 480-483.
16. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment. *J Clin. Endocrinol Metab.*, 2016; 101(5): 1889–1916.
17. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology.* 14th ed. Philadelphia: Elsevier; 2021; 935-937.
18. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 179-181.

19. Goodman HM. *Basic Medical Endocrinology.* 4th ed. San Diego: Academic Press, 2009; 240-242.
20. Molitch ME. Diagnosis and Treatment of Acromegaly. *Endocrinol Metab Clin North Am.*, 2019; 48(3): 577-589.
21. Widmaier EP, Raff H, Strang KT. *Vander's Human Physiology: The Mechanisms of Body Function.* 15th ed. McGraw-Hill Education; 2022; 482-484.
22. Ho KK. GH deficiency in adults: physiological and clinical implications. *Endocr Rev.*, 2017; 38(3): 336-376.
23. Cook DM, Yuen KC, Biller BM. Adult growth hormone deficiency: clinical features, diagnosis, and treatment. *Endocr Pract.*, 2019; 25(8): 816-832.
24. Melmed S. Medical progress: Acromegaly. *N Engl J. Med.*, 2020; 382: 255-265.
25. Molitch ME. Diagnosis of GH disorders: dynamic testing. *J Clin Endocrinol Metab.* 2016; 101(3): 963-974.
26. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology.* 14th ed. Philadelphia: Elsevier; 2021; 939-940.
27. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 226-227.
28. Goodman HM. *Basic Medical Endocrinology.* 4th ed. San Diego: Academic Press; 2009; 263-264.
29. Melmed S. Pathogenesis and diagnosis of prolactinoma. *Endocrinol Metab Clin North Am.*, 2020; 49(4): 433-445.
30. Schlechte JA. Clinical practice: Prolactinoma. *N Engl J Med.*, 2019; 382: 295-305.
31. Molitch ME. Disorders of prolactin secretion. *Endocr Rev.*, 2017; 38(5): 459-496.
32. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology.* 14th ed. Philadelphia: Elsevier, 2021; 945-946.
33. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 243-244.
34. Goodman HM. *Basic Medical Endocrinology.* 4th ed. San Diego: Academic Press; 2009; 278-279.
35. Bornstein SR et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.*, 2016; 101(2): 364–389.
36. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. *Lancet.* 2015; 386: 913–927.

37. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.*, 2008; 93(5): 1526–1540.
38. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology*. 14th ed. Philadelphia: Elsevier, 2021; 947-948.
39. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology*. 14th ed. Philadelphia: Elsevier, 2020; 270-271.
40. Braverman LE, Cooper DS. *Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text*. 11th ed. Philadelphia: Wolters Kluwer, 2021; 95-97.
41. Persani L. Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. *J Clin. Endocrinol Metab.*, 2012; 97(9): 3068–3078.
42. Beck-Peccoz P, Persani L. Thyrotropin-secreting pituitary adenomas. *Endocr Rev.*, 1994; 15(4): 682–715.
43. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: American Thyroid Association Task Force. *Thyroid.*, 2014; 24(12): 1670–1751.
44. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology*. 14th ed. Philadelphia: Elsevier, 2021; 1011-1013.
45. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology*. 14th ed. Philadelphia: Elsevier, 2020; 659-661.
46. Ganong WF. *Review of Medical Physiology*. 26th ed. New York: McGraw-Hill, 2019; 415-416.
47. Plant TM, Zeleznik AJ. Knobil and Neill's Physiology of Reproduction. 4th ed. Academic Press, 2015; 277-279.
48. Bonomi M, Vezzoli V, Krausz C, et al. Characteristics of hypogonadotropic hypogonadism in males and females. *Endocr Rev.*, 2018; 39(5): 691–707.
49. Beckers A, Aaltonen LA, Daly AF. Rare pituitary adenomas. *Endocr Rev.*, 2018; 39(5): 489–519.
50. Sinha SK, Sahoo JP, et al. Gonadotropin disorders: Clinical spectrum and management. *Indian J. Endocrinol. Metab.*, 2019; 23(3): 278–286.
51. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology*. 14th ed. Philadelphia: Elsevier, 2021, 353–355.
52. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology*. 14th ed. Philadelphia: Elsevier, 2020; 308–310.

53. Verbalis JG. Disorders of water balance: Diabetes insipidus and SIADH. *Endocrinol Metab Clin North Am.*, 2016; 45(3): 679–694.
54. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. *N Engl J Med.*, 2007; 356(20): 2064–2072.
55. Hall JE, Guyton AC. *Guyton and Hall Textbook of Medical Physiology.* 14th ed. Philadelphia: Elsevier, 2021; 356–357.
56. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 315–316.
57. Cunningham F, Leveno K, Bloom S, Dashe J, Hoffman B, Casey B, et al. *Williams Obstetrics.* 25th ed. New York: McGraw-Hill, 2018; 823–825.
58. Hofmeyr GJ, et al. Oxytocin: pharmacology and clinical use. *Best Pract. Res. Clin. Obstet Gynaecol.*, 2020; 68: 14–26.
59. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 320–322.
60. Johannsson G, et al. Long-acting growth hormone preparations: Current status and future perspectives. *Endocr. Rev.*, 2021; 42(5): 658–680.
61. Colao A, et al. Treatment of acromegaly: A 2021 update. *J Clin Endocrinol Metab.*, 2021; 106(9): 2521–2534.
62. Katznelson L, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. *J Clin. Endocrinol Metab.*, 2014; 99(11): 3933–3951.
63. van der Lely AJ, et al. Pegvisomant in acromegaly: Clinical efficacy and safety. *Nat Rev Endocrinol.*, 2020; 16(9): 513–524.
64. Melmed S, et al. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier, 2020; 356–358.
65. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. *Endocr Rev.*, 2006; 27(5): 485–534.
66. Colao A, et al. Cabergoline in the treatment of hyperprolactinemia: Safety and efficacy. *J Clin Endocrinol Metab.*, 2011; 96(9): E1431–E1440.
67. Melmed S. Pathogenesis and treatment of prolactinomas. *Nat Rev Endocrinol.*, 2010; 6(5): 267–276.
68. Schlechte JA. Clinical practice. Prolactinoma. *N Engl J Med.*, 2003; 349: 2035–2041.
69. Nieman LK, et al. *Williams Textbook of Endocrinology.* 14th ed. Philadelphia: Elsevier; 2020; 478–480.

70. Mackay MT, et al. Treatment of infantile spasms: An evidence-based approach. *Epilepsia.,* 2012; 53(9): 1503–1518.
71. Food and Drug Administration (FDA). Acthar Gel (repository corticotropin injection) Prescribing Information. Mallinckrodt, 2021; 3–6.
72. Montero-Melendez T. ACTH: The forgotten therapy. *Semin Immunol.,* 2015; 27(3): 216–226.
73. Bornstein SR, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.,* 2016; 101(2): 364–389.
74. Pacini F, et al. Recombinant human TSH in the management of differentiated thyroid cancer. *Endocr Rev.,* 2012; 33(6): 992–1030, 995–997.
75. Schlumberger M, et al. Recombinant human thyrotropin for thyroid remnant ablation. *N Engl J Med.,* 1998; 338: 515–522, 516–518.
76. Thyrogen [Prescribing Information]. Cambridge, MA: Genzyme Corp, 2021; 3–5.
77. Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid.,* 2016; 26(10): 1343–1421, 1347–1348.
78. Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogs. *N Engl J Med.* 1991; 324(2): 93–103, 94–96.
79. Schally AV, et al. Leuprolide: current status of clinical applications. *Cancer.,* 1989; 63(3): 457–471, 460–462.
80. Wu FC, et al. Suppression of gonadal function with GnRH agonists. *J Clin. Endocrinol Metab.,* 1987; 65(4): 738–743, 740–741.
81. Olivennes F, et al. GnRH antagonists in assisted reproduction. *Hum Reprod Update.,* 1996; 2(5): 403–418, 405–407.
82. Devroey P, et al. Recombinant human follicle-stimulating hormone (FSH) in assisted reproduction. *Fertil Steril.,* 1998; 70(3): 651–654, 652–653.
83. Cole LA. hCG and its clinical applications. *Clin Obstet Gynecol.,* 2012; 55(1): 215–229, 217–219.
84. Robertson GL. Antidiuretic hormone. *Endocrinol Metab Clin North Am.,* 2001; 30(3): 671–694, 674–675.
85. Miller M, et al. Desmopressin in the treatment of central diabetes insipidus. *Clin Endocrinol (Oxf).* 1986; 24(5): 443–449, 444–446.

86. Mannucci PM, et al. Desmopressin and hemostasis. *Blood.*, 1988; 71(3): 628–635, 629–631.
87. Schrier RW, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med.*, 2006; 355(20): 2099–2112, 2101–2103.
88. Verbalis JG. Vasopressin receptor antagonists in hyponatremia. *Am. J. Med.*, 2006; 119(7 Suppl 1): S87–S92, S89–S90.
89. Morelli A, et al. Terlipressin for hemodynamic support in septic shock. *Crit Care Med.* 2009; 37(2): 601–608, 603–605.
90. Cunningham FG, et al. *Williams Obstetrics.* 25th ed. New York: McGraw-Hill; 2018; 465–470.
91. Hofmeyr GJ, et al. Oxytocin for the prevention of postpartum hemorrhage. *Cochrane Database Syst Rev.*, 2013; (7): CD001808, 3–5.
92. Valenzuela GJ, et al. Atosiban versus placebo in the treatment of preterm labor. *Obstet Gynecol.*, 2000; 95(4): 639–645, 640–642.
93. Harvey S, Martinez-Moreno CG. Growth Hormone: Therapeutic Possibilities-An Overview. Int J Mol Sci., 2018 Jul.
94. Chasseloup F, Bernard V, Chanson P. Prolactin: structure, receptors, and functions. Rev Endocr. Metab Disord., 2024 Dec.
95. Hu D, Li J, Zhuang Y, Mao X. Adrenocorticotropic hormone: An expansion of our current understanding of the treatment for nephrotic syndrome. Steroids., 2021 Dec.
96. Luo B, Yu Z, Li Y. Thyroid hormone disorders and sepsis. Biomed Mater Eng., 2017.
97. Pratama G, Wiweko B, Asmarinah, Widyahening IS, Andraini T, Bayuaji H, Hestiantoro A. Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis. Sci. Rep., 2024 Apr.
98. Tripathi A, Kumar M, Kalita J, Kant S, Misra UK. Renin, antidiuretic hormone (ADH), and ADH receptor levels in cerebral salt wasting associated with tuberculous meningitis. Neurol. Sci., 2022 May.
99. Hermesch AC, Kernberg AS, Layoun VR, Caughey AB. Oxytocin: physiology, pharmacology, and clinical application for labor management. Am. J. Obstet. Gynecol., 2024 Mar.